Polymorphisms in the cytochrome P450 CYP1A2 gene (CYP1A2) in colorectal cancer patients and controls: allele frequencies, linkage disequilibrium and influence on caffeine metabolism
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
Aims Several single nucleotide polymorphisms (SNPs) of the cytochrome P450 enzyme 1A2 gene (CYP1A2) have been reported. Here, frequencies, linkage disequilibrium and phenotypic consequences of six SNPs are described. Methods From genomic DNA, 114 British Caucasians (49 colorectal cancer cases and 65 controls) were genotyped for the CYP1A2 polymorphisms −3858G→A (allele CYP1A2*1C), −2464T→delT (CYP1A2*1D), −740T→G (CYP1A2*1E and *1G), −164A→C (CYP1A2*1F), 63C→G (CYP1A2*2), and 1545T→C (alleles CYP1A2*1B, *1G, *1H and *3), using polymerase chain reaction–restriction fragment length polymorphism assays. All patients and controls were phenotyped for CYP1A2 by h.p.l.c. analysis of urinary caffeine metabolites. Results In 114 samples, the most frequent CYP1A2 SNPs were 1545T→C (38.2% of tested chromosomes), −164A→C (CYP1A2*1F, 33.3%) and −2464T→delT (CYP1A2*1D, 4.82%). The SNPs were in linkage disequilibrium: the most frequent constellations were found to be −3858G/−2464T/−740T/−164A/63C/1545T (61.8%), −3858G/−2464T/−740T/−164C/63C/1545C (33.3%), and −3858G/−2464delT/−740T/−164A/63C/1545C (3.51%), with no significant frequency differences between cases and controls. In the phenotype analysis, lower caffeine metabolic ratios were detected in cases than in controls. This was significant in smokers (n = 14, P = 0.020), and in a subgroup of 15 matched case‐control pairs (P = 0.007), but it was not significant in nonsmokers (n = 100, P = 0.39). There was no detectable association between CYP1A2 genotype and caffeine phenotype. Conclusions (i) CYP1A2 polymorphisms are in linkage disequilibrium. Therefore, only −164A→C (CYP1A2*1F) and −2464T→delT (CYP1A2*1D) need to be analysed in the routine assessment of CYP1A2 genotype; (ii) in vivo CYP1A2 activity is lower in colorectal cancer patients than in controls, and (iii) CYP1A2 genotype had no effect on phenotype (based on the caffeine metabolite ratio). However, this remains to be confirmed in a larger study.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bertz, R. J., & Granneman, G. R. (1997) · Clinical Pharmacokinetics · doi:10.2165/00003088-199732030-00004 · Cited by 755
Sachse, C., Brockmöller, J., Bauer, S., & Roots, I. (1999) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1999.00898.x · Cited by 751
Butler, M. A., Iwasaki, M., Guengerich, F. P., & Kadlubar, F. F. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.20.7696 · Cited by 638
Lang, N. P., Butler, M. A., Massengill, J., Lawson, M., Stotts, R. C., Hauer‐Jensen, M., & Kadlubar, F. F. (1994) · PubMed · Cited by 430
Butler, M. A., Lang, N. P., Young, J. F., Caporaso, N. E., Vineis, P., Hayes, R. B., Teitel, C. H., Massengill, J. P., Lawsen, M. F., & Kadlubar, F. F. (1992) · Pharmacogenetics · doi:10.1097/00008571-199206000-00003 · Cited by 419
Model-Free Analysis and Permutation Tests for Allelic Associations
Zhao, J. H., Curtis, D., & Sham, P. C. (2000) · Human Heredity · doi:10.1159/000022901 · Cited by 417
Nomenclature for human CYP2D6 alleles
Daly, A. K., Brockmoller, J., Broly, F., Eichelbaum, M., Evans, W. E., Gonzalez, F. J., Huang, J. D., Idle, J. R., Ingelman-Sundberg, M., Ishizaki, T., et al. (1996) · Pharmacogenetics · doi:10.1097/00008571-199606000-00001 · Cited by 396
Self-citationNakajima, M., Yokoi, T., Mizutani, M., Kinoshitah, M., Funayama, M., & Kamataki, T. (1999) · Journal of Biochemistry · doi:10.1093/oxfordjournals.jbchem.a022352 · Cited by 346
Boobis, A. R., Lynch, A. M., Murray, S., de la Torre, R., Solans, A., Farré, M., Segura, J., Gooderham, N. J., & Davies, D. S. (1994) · PubMed · Cited by 261
Self-citationUse of caffeine metabolite ratios to explore CYP1A2 and xanthine oxidase activities
Kalow, W., & Tang, B.-K. (1991) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1991.176 · Cited by 261
Independence tests for VNTR alleles defined as quantile bins.
Weir, B. S. (1993) · PubMed · Cited by 217
Caffeine as a metabolic probe: Exploration of the enzyme-inducing effect of cigarette smoking
Kalow, W., & Tang, B.-K. (1991) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1991.8 · Cited by 213
Lampe, J. W., King, I. B., Li, S., Grate, M. T., Barale, K. V., Chen, C., Feng, Z., & Potter, J. D. (2000) · Carcinogenesis · doi:10.1093/carcin/21.5.157 · Cited by 190
A urinary metabolite ratio that reflects systemic caffeine clearance
Campbell, M. E., Spielberg, S. P., & Kalow, W. (1987) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1987.126 · Cited by 189
Quattrochi, L. C., Vu, T., & Tukey, R. H. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)37466-5 · Cited by 178
Nakajima, M., Yokoi, T., Mizutani, M., Shin, S., Kadlubar, F. F., & Kamataki, T. (1994) · PubMed · Cited by 141
Chida, M., Yokoi, T., Fukui, T., Kinoshita, M., Yokota, J., & Kamataki, T. (1999) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.1999.tb00832.x · Cited by 118
Genotyping for polymorphisms in xenobiotic metabolism as a predictor of disease susceptibility.
Daly, A. K., Cholerton, S., Armstrong, M., & Idle, J. R. (1994) · Environmental Health Perspectives · doi:10.1289/ehp.94102s955 · Cited by 101
Human cytochrome P450 (CYP) genes: recommendations for the nomenclature of alleles
Ingelman‐Sundberg, M., Daly, A. K., Oscarson, M., & Nebert, D. W. (2000) · Pharmacogenetics · doi:10.1097/00008571-200002000-00012 · Cited by 85
Chevalier, D., Cauffiez, C., Allorge, D., Lo‐Guidice, J., Lhermitte, M., Lafitte, J., & Broly, F. (2001) · Human Mutation · doi:10.1002/humu.49 · Cited by 71
Polymorphisms of CYP1A1 and GSTM1 influence the in vivo function of CYP1A2
Macleod, S. L., Sinha, R., Kadlubar, F. F., & Lang, N. P. (1997) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/s0027-5107(97)00036-5 · Cited by 66
Detailed modelling of caffeine metabolism and examination of the CYP1A2 gene
Welfare, M., Aitkin, M. A., Bassendine, M. F., & Daly, A. K. (1999) · Pharmacogenetics · doi:10.1097/00008571-199906000-00012 · Cited by 50
Heterocyclic amines: evaluation of their role in diet associated human cancer
Gooderham, N. J., MURRAY, S., Lynch, A. M., EDWARDS, R. J., Yadollahi‐Farsani, M., Bratt, C., Rich, K. J., Zhao, K., Murray, B. P., Bhadresa, S., et al. (1996) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1996.37513.x · Cited by 46
Self-citationChevalier, D., Allorge, D., Lo‐Guidice, J., Cauffiez, C., Lhermitte, M., Lafitte, J., & Broly, F. (2001) · Human Mutation · doi:10.1002/humu.48 · Cited by 38
Aitchison, K. J., Gonzalez, F. J., Quattrochi, L. C., Sapone, A., Zhao, J. H., Zaher, H., Elizondo, G., Bryant, C., Munro, J., Collier, D. A., et al. (2000) · Pharmacogenetics · doi:10.1097/00008571-200011000-00004 · Cited by 36
Spigelman, A., Farmer, K. C., Oliver, S., Nugent, K. P., Bennett, P. N., Notarianni, L. J., Dobrocký, P., & Phillips, R. K. S. (1995) · Gut · doi:10.1136/gut.36.2.251 · Cited by 20
Cited by
Kirchheiner, J., Nickchen, K., Bauer, M., Wong, M.-L., Licinio, J., Roots, I., & Brockmöller, J. (2004) · Molecular Psychiatry · doi:10.1038/sj.mp.4001494 · Cited by 724
Pregnancy-Induced Changes in Pharmacokinetics: A Mechanistic-Based Approach
Anderson, G. D. (2005) · Clinical Pharmacokinetics · doi:10.2165/00003088-200544100-00001 · Cited by 648
Turesky, R. J., & Le Marchand, L. (2011) · Chemical Research in Toxicology · doi:10.1021/tx200135s · Cited by 337
Assessment of CYP1A2 Activity in Clinical Practice: Why, How, and When?
Faber, M. S., Jetter, A., & Fuhr, U. (2005) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2005.pto_973160.x · Cited by 283
Zhou, S.-F., Wang, B., Yang, L.-P., & Liu, J.-P. (2010) · Drug Metabolism Reviews · doi:10.3109/03602530903286476 · Cited by 262
Metadata
- Authors
- Sachse, C., Bhambra, U., Smith, G., Lightfoot, T. J., Barrett, J. H., Scollay, J., Garner, R. C., Boobis, A. R., Wolf, C. R., Gooderham, N. J., & The Colorectal Cancer Study Group
- Venue
- British Journal of Clinical Pharmacology
- Publisher
- Wiley
- Published
- 2003-01
- Volume
- 55
- Issue
- 1
- Pages
- 68-76
- ISSN
- 0306-5251 (ISSN-L)
- 1365-2125
- OpenAlex
- W1560943036
- Cited by
- 174
- References
- 26
- FWCI
- 11.42
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.